Trials / Completed
CompletedNCT03877952
Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants
A Phase 1 Open-label, Single-dose Study Designed to Assess the Mass Balance Recovery and Metabolite Profile and to Identify Metabolite Structures for [14C]-CORT125281 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Corcept Therapeutics · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-CORT125281 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 14C-CORT125281 | 14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C |
Timeline
- Start date
- 2018-09-13
- Primary completion
- 2018-11-01
- Completion
- 2018-11-02
- First posted
- 2019-03-18
- Last updated
- 2019-03-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03877952. Inclusion in this directory is not an endorsement.